Summer 2026

Business Data Analytics Intern

Channel Coverage

Posted on 5/24/2026

Becton Dickinson

Becton Dickinson

10,001+ employees

Global medical devices and diagnostics provider

Compensation Overview

$23.96 - $33.54/hr

New Mexico, USA + 51 more

More locations: Washington, USA | Kansas, USA | Pennsylvania, USA | North Dakota, USA | Oregon, USA | Delaware, USA | Iowa, USA | Milpitas, CA, USA | California, USA | Washington, DC, USA | Vermont, USA | Wyoming, USA | Texas, USA | Montana, USA | Jackson Township, NJ, USA | Florida, USA | Waterbury, CT, USA | Nevada, USA | South Carolina, USA | South Dakota, USA | Georgia, USA | Arizona, USA | Concord, NH, USA | Mississippi, USA | Tennessee, USA | Virginia, USA | Arkansas, USA | Minnesota, USA | Colorado, USA | Nebraska, USA | Rhode Island, USA | Utah, USA | Hawaii, United States | Kentucky, USA | West Virginia, USA | New York, NY, USA | Maryland, USA | Wisconsin, USA | Maine, USA | Massachusetts, USA | North Carolina, USA | Oklahoma, USA | Missouri, USA | Ohio, USA | Indiana, USA | Louisiana, USA | Alaska, USA | Michigan, USA | Illinois, USA | Alabama, USA | Idaho, USA

Hybrid

Minimum 4 days in-office per week.

Bachelor's, Master's, MBA

Category
Data & Analytics
Required Skills
Python
R
SQL
Data Analysis
Excel/Numbers/Sheets

Get referred to Becton Dickinson

See people who can refer or advise you

Requirements
  • Current Bachelor's degree student.
  • Strong analytical and quantitative skills, with hands-on experience working with real-world business data, including data extraction, cleansing, validation, and preparation for analysis and basic modeling.
  • Proficiency with analytical tools such as Excel, SQL, Python, R, or comparable platforms.
  • Demonstrated ability to translate complex datasets into clear, actionable business insights.
  • Strong written and verbal communication skills, with the ability to effectively engage cross-functional stakeholders.
  • Interest in life sciences, diagnostics, analytical instrumentation, or healthcare markets.
  • Self-starter with strong attention to detail and the ability to work independently in a fast-paced, matrixed environment.
Responsibilities
  • Design, develop, and implement a data-driven framework to identify, evaluate, and select business partners in support of a unified channel coverage model across Waters and BD.
  • Partner closely with sales, marketing, commercial excellence, and product management teams across both organizations to align on data requirements, validate assumptions, and ensure the model meets operational and commercial needs.
  • Gather, integrate, and analyze diverse data sources, including sales history, installed base data, product portfolio, market coverage, and organizational structures.
  • Develop dashboards and visualizations that clearly synthesize insights and effectively communicate recommendations to stakeholders.
  • Prepare and deliver weekly progress updates highlighting key accomplishments, risks, and next steps.
  • Document analytical assumptions, data sources, and model logic to ensure transparency, scalability, and continuity beyond the duration of the internship.
Desired Qualifications
  • Current MBA or Master’s degree student with a concentration in Business Analytics, Data Science, Marketing Analytics, or a related field.
  • Experience with data visualization tools (e.g., Power BI, Tableau) and/or machine learning techniques.

BD is a global medical technology company serving hospitals, labs, and healthcare providers with products across BD Medical, Life Sciences, and Interventional. Its offerings include medication management and delivery devices, safe specimen collection and transport systems, and minimally invasive surgical instruments. Its products help safe medication administration, preserve specimen integrity for diagnostics, and enable less-invasive procedures, saving time and improving outcomes. BD differentiates itself with a broad end-to-end portfolio, global reach, and focus on quality, safety, and service to support care across regions; its goal is to improve patient outcomes, lower costs, and increase efficiency in care environments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Franklin Lakes, New Jersey

Founded

1961

Get referred to Becton Dickinson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q3 fiscal 2026 revenue rose 5.4%, and free cash flow jumped 44.6%.
  • EMS launched semaglutide in Brazil using BD's Vystra pen platform on July 29, 2026.
  • BD completed PREVENT enrollment on August 12, 2026, advancing Phasix label expansion.

What critics are saying

  • FDA recalled BD intraosseous needle sets on July 31, after four deaths and 45 injuries.
  • Hernia mesh litigation still hangs over Bard, with roughly 24,000 claims pending in 2026.
  • Repeated quality failures can sink hospital trust and trigger existential procurement bans.

What makes Becton Dickinson unique

  • BD owns installed hospital workflows across medication delivery, vascular access, and interventional care.
  • The February 2026 Waters spin-off made BD a focused pure-play medtech operator.
  • Phasix, Vystra, and CIRSE training deepen BD's regenerative and procedural ecosystems.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

10%

1 year growth

10%

2 year growth

10%
MedTech Dive
Aug 13th, 2026
BD fully enrolls trial of resorbable mesh for hernia prevention.

BD fully enrolls trial of resorbable mesh for hernia prevention. BD called completing enrollment in the study "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Published Aug. 13, 2026 Dive brief: * BD said Wednesday it has completed enrollment in a clinical trial of resorbable mesh for preventing incisional hernias after open abdominal surgery. * Investigators enrolled 477 patients across 32 sites in the U.S. and Europe to compare the effect of BD's Phasix mesh and primary suture closure on the rate of incisional hernias. * BD will follow patients through the trial's primary endpoint at 24 months, beyond which it expects to use the data to seek Food and Drug Administration authorization for the indication. Dive insight: Incisional hernia is a serious and relatively common postoperative complication of elective abdominal surgeries where a large incision is made through the abdominal wall. BD's Phasix is a resorbable mesh. CR Bard, which BD bought for $24 billion in 2017, received FDA clearance in 2015 for Phasix in settings including hernia repair. Later, long-term data on the device confirmed the absence of mesh complications such as pain and infection. BD has faced lawsuits over adverse events allegedly linked to Bard meshes made from other materials. By completing enrollment in its PREVENT trial, BD took a step toward expanding the Phasix label to cover the prophylactic use of the device in patients undergoing elective open midline laparotomy surgery. Evaluating Phasix in hernia prevention builds on "decades of innovation in abdominal wall surgery" and will generate evidence that could "help broaden the role of regenerative technologies for patients at risk of post-surgical complications," Rian Seger, worldwide president of surgery at BD, said in a statement. BD called completion of enrollment in the clinical trial "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Last week, the company reported double-digit growth in sales of its infection prevention and advanced tissue regeneration products in the third quarter of its financial year. Discussing tissue regeneration on BD's third-quarter earnings call, CEO Thomas Polen said the company expects "strong growth going forward." Polen supported the expectations by highlighting clinical trials that the company is running to bring its biomaterial "into new indications to continue to expand our presence in those spaces."

Yahoo Finance
Aug 9th, 2026
BD up 6.8% on Q3 beat, GLP-1 pen partnerships boost biologic delivery outlook

Becton Dickinson reported third-quarter fiscal 2026 sales of $4,983 million, whilst net income fell to $377 million. The medical technology company modestly raised its full-year outlook for low single-digit revenue growth. BD highlighted momentum in biologic drug delivery and GLP-1 partnerships, including a new semaglutide pen collaboration with EMS in Brazil. The company's Vystra Injection Pen platform is gaining traction in chronic disease treatment. FX-neutral revenue grew faster than expected, leading management to nudge guidance higher. However, the sharp drop in year-to-date net income and recent one-off loss raise questions about earnings quality. The company maintained its $4.20 annual dividend. Shares rose 6.8% following the results, though some analysts suggest the stock remains undervalued by approximately 25%.

Yahoo Finance
Aug 7th, 2026
BD reports Q3 fiscal 2026 results with $5B revenue up 5.4% and adjusted EPS of $3.23

BD reported third quarter fiscal 2026 revenue of $5.0 billion, up 5.4% as reported and 4.4% on a foreign exchange-neutral basis. GAAP diluted earnings per share from continuing operations reached $1.64, whilst adjusted diluted EPS came in at $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion. Free cash flow rose 44.6% to $1.7 billion. The medical technology company updated its full-year guidance, expecting revenue growth towards the high end of its range whilst raising the midpoint of its adjusted diluted EPS guidance. The results represent BD's first full quarter following the 9 February 2026 spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation.

AMS Group, LLC
Aug 1st, 2026
Becton Dickinson issues recall on certain lots of needle sets used for emergency IV access.

Becton Dickinson issues recall on certain lots of needle sets used for emergency IV access. July 31 (Reuters) - Becton Dickinson said on Friday it is issuing a recall on certain lots of medical needle sets in the U.S. after users reported difficulty in removing a part of the device after using it on patients. Here are some details: - The product, called an intraosseous needle set, is used to deliver fluids and medicine quickly into a patient's bone when a regular IV line cannot be used fast enough. This is often done in emergencies, such as cardiac arrest or severe trauma. - Becton said the issue involves a part called the obturator, or stylet, which sometimes cannot be removed after the needle is inserted. - The company said this incident can happen if the drill used to insert the needle is not pulled straight back, or if the obturator is rotated the wrong way when taken out. - As of June 2026, BD said it had received 75 complaints and 45 reports of serious injury related to the problem. The company also said four patients died when the part could not be removed during resuscitation efforts for people who had suffered cardiac arrest outside a hospital. - The affected needle sets were made with parts slightly out of the normal size range and were shipped between September 30, 2024, and June 12, 2026. - The recall does not include the intraosseous powered driver, which is the tool used to insert the needles. - BD said that if the obturator cannot be removed, medical staff may need to get a new needle or switch to another way of giving treatment, like a peripheral IV catheter. That delay could be dangerous, especially for critically ill patients, the company said. - The U.S. Food and Drug Administration has been informed about the recall, BD said. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shailesh Kuber)

Life Sciences BC
Jul 29th, 2026
EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch.

EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch. July 29, 2026 Collaboration pairs leadership in pharmaceuticals and advanced drug delivery technology to support a consistent, reliable treatment experience for metabolic disease patients. * FRANKLIN LAKES, N.J. and SÃO PAULO - BD (Becton, Dickinson and Company) a leading global medical technology company, and EMS, one of Brazil's leading pharmaceutical companies, announced their collaboration in the launch of a semaglutide therapy in Brazil. This collaboration and launch underscore a shared commitment to addressing patients' ongoing healthcare challenges associated with chronic diseases, including obesity and type 2 diabetes. Global demand for GLP-1 therapies has highlighted the critical need for delivery systems that enable safe, accurate, and consistent dosing for patients. Many patients face challenges with ease of use, confidence with self-injection and adherence to treatment, making intuitive and reliable delivery solutions increasingly important. EMS's semaglutide utilizes BD's established injection pen platform, which features an intuitive design built for ease of use. The BD Vystra(TM) Injection Pen platform reflects BD's deep expertise in drug delivery systems design and manufacturing, supporting scalable solutions that can help meet rising demand for injectable therapies. "BD's partnership with EMS introduces a critical treatment option backed by scalable, patient-centric delivery technology," said Patrick Jeukenne, Worldwide President of Pharmaceutical Systems at BD. "By combining this therapy with BD's established pen platform, patients benefit from a proven, research backed design that supports usability for self-injection." "Launching our semaglutide marks an important step in expanding access to advanced metabolic therapies in Brazil," said Gabriel Sanchez, Vice President of EMS. "By co-creating with BD, we're able to provide solutions that meet the needs of our clinicians and patients alike." About BD BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health(TM) by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X or Instagram @becton_dickinson. About EMS EMS is one of Brazil's leading pharmaceutical companies, with more than 60 years of experience developing and delivering innovative, high-quality therapies. The company operates across prescription medicines, generics and OTC, with a growing global footprint spanning more than 60 countries. EMS continues to invest in advanced manufacturing and R&D, including peptide capabilities to support GLP 1 therapies for obesity and type 2 diabetes. | Contacts: | / | | Media | Investors | | Matt Marcus VP, Public Relations [email protected] | Shawn Bevec SVP, Investor Relations [email protected] | SOURCE BD (Becton, Dickinson and Company) Original source here.

INACTIVE